PFE.HM - Pfizer Inc
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 35.05 |
| Open | 35.05 |
| Bid | 34.50 x 0 |
| Ask | 34.55 x 0 |
| Day's Range | 34.70 - 35.30 |
| 52 Week Range | 33.85 - 52.50 |
| Volume | |
| Avg. Volume | 258 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Jul 26, 2023 - Jul 31, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
Investor's Business DailyPfizer's Approach To Hemophilia Is 'Certainty Differentiated' — Here's Why Shares Fell
Pfizer said Tuesday its experimental hemophilia treatment cut down on bleeding episodes in a pivotal study. But Pfizer stock dipped.
ZacksValneva (VALN) Stock Down 53% in the Past Year: Here's Why
The European Commission's revised advance purchase agreement jeopardizes Valneva's (VALN) COVID-19 vaccine program.
ZacksPfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- Reuters
Pfizer's hemophilia therapy reduces bleeding in late-stage study
U.S. drugmaker Pfizer Inc said on Tuesday late-stage study data for its experimental hemophilia therapy showed superiority to the current standard of care treatment in reducing bleeding rates in patients. The therapy, marstacimab, met its main trial goal, demonstrating superiority to factor replacement therapies, with a 92% reduction in bleeding in patients with severe hemophilia A and moderately severe to severe hemophilia B, Pfizer said. Hemophilia hampers the body's ability to make blood-clotting proteins, leading to prolonged bleeding following injuries or surgery, and it primarily affects males, according to government data.
Business WirePfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial
NEW YORK, May 30, 2023--Pfizer Inc. (NYSE: PFE) today announced that the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating marstacimab has met its primary endpoints, having demonstrated statically significant and clinically meaningful effects. Marstacimab, a novel, investigational anti-tissue factor pathway inhibitor (anti-TFPI) being studied for the treatment of hemophilia A or B for people without inhibitors to Factor VIII (FVIII) or Factor IX (FIX), was administered weekly with fl
Motley FoolPfizer's Heading for a Patent Cliff. Is the Stock Still a Buy?
The company also continues to benefit from sales of blockbusters including blood thinner Eliquis and oncology drug Ibrance. In fact, Pfizer expects patent losses alone to lead to $17 billion in lost revenue from 2025 through 2030. In spite of these upcoming obstacles, is Pfizer still a buy?
ZacksEMA Panel Endorses Novavax's (NVAX) COVID Jab for Full Approval
Novavax's (NVAX) protein-based COVID-19 vaccine gets recommendation for full marketing authorization in COVID-19 patients from European Medicines Agency.
Motley FoolThe Top Healthcare Stocks to Buy With $100
The healthcare industry is diverse and complex, with longtime staples and emerging disruptors to fit your portfolio -- and it also doesn't need to cost an arm and a leg. Here are several possibilities to consider, each playing a different role in the healthcare system. In an industry where size matters, Pfizer (NYSE: PFE) is one of the industry's most prominent players, with a market cap of over $200 billion.
Motley FoolInvesting $43 in This Stock per Week for 5 Years Could Give You $500 in Annual Dividend Income
If you're thinking of investing in Pfizer (NYSE: PFE) to generate some passive income from your portfolio, you won't need to spend very much to do so, provided that you're willing to play the long game. Building up a passive income stream is often a lot more manageable when you can do it piece by piece rather than paying out a large lump sum. Dollar-cost averaging (DCA) refers to buying a few shares of a stock here and there over a period of time so that you don't need a lump sum to reach your target position size.
Motley Fool3 No-Brainer Stocks to Buy for Under $100 Right Now
Here's why they chose CRISPR Therapeutics (NASDAQ: CRSP), Novocure (NASDAQ: NVCR), and Pfizer (NYSE: PFE). David Jagielski (CRISPR Therapeutics): Shares of CRISPR Therapeutics are trading below $70, but it may not be long before they take off. The company has a promising gene-editing therapy in exa-cel for rare blood disorders beta-thalassemia and sickle cell disease that it has been working on with Vertex Pharmaceuticals.
Investor's Business DailyEli Lilly Could Launch Its Rival To Novo Nordisk's Weight-Loss Drug A Year Earlier Than Expected
An analyst expects Lilly to launch a competitor in weight-loss drugs a year earlier than expected, giving Eli Lilly stock a chance to shine.
The Wall Street JournalNext Covid Boosters to Target New Strain
Health authorities and vaccine makers are moving toward targeting the next shot on a form of the XBB strain that is now circulating widely in the U.S.
Barrons.comDrugmakers Released a Ton of New Cancer Treatment Data. The Biggest Developments.
Ahead of the American Society of Clinical Oncology meeting, Pfizer, Merck, and other companies released scientific abstracts of papers that they'll present at the annual meeting.
ZacksPfizer's (PFE) COVID-19 Oral Treatment Gets FDA Nod in Adults
Per the FDA, Pfizer's (PFE) Paxlovid is the first oral antiviral pill approved in the United States to treat COVID-19 in adults. The drug was granted emergency use authorization by the FDA in 2021.
Yahoo Finance VideoPfizer weight loss drug may be as effective as competitors: Study
Yahoo Finance Live health care reporter Anjalee Khemlani details the clinical trial results of Pfizer's weight loss drug Danuglipron, how it compares to Novo Nordisk's Ozempic, and examines the adoption of weight loss drugs in the health and wellness space.
BenzingaAmended European Deal For BioNTech-Pfizer's Covid-19 Vaccines Allows Reduced Purchases
The European Commission (EC) had agreed with BioNTech SE (NASDAQ: BNTX) and Pfizer Inc (NYSE: PFE) on adapting the existing contract on vaccines against Covid-19, including a reduction in the quantity of doses purchased by EU countries under the contract and pushing the delivery deadline to 2026. "The amendment to the existing vaccines supply contract takes into account the improved epidemiological situation while continuing to ensure access to the latest available version of the vaccine should
- Financial Times
Brussels and Pfizer agree deal to cut supply of Covid vaccines
Revised contract addresses concerns over costly glut of unwanted shots as public health threat wanes
- Reuters
UPDATE 2-EU, Pfizer/BioNTech announce amendment to COVID vaccine contract
The European Union and drugmakers Pfizer and BioNTech said on Friday they had reached a deal to amend a COVID-19 vaccine contract, cutting the number the EU must buy and pushing the delivery deadline to 2026. The agreement, first reported by Reuters earlier on Friday, comes after months of talks and amid pressure on Brussels from EU governments to secure a change to the contract because of a global glut of COVID-19 vaccine doses and low demand for boosters. The amended contract matches "evolving needs", said EU Health Commissioner Stella Kyriakides in a statement.
Motley FoolWhy Pfizer Stock Slipped by 2% Today
The market wasn't impressed by the company's latest drug approval, plus an analyst cut her price target on the shares.
PR NewswireAstellas Highlights Continued Delivery of Strong Cancer Portfolio and Pipeline at 2023 ASCO Annual Meeting
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will share new research from across its expanding portfolio of approved and investigational cancer therapies during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting from June 2-6. A total of 15 abstracts, covering three approved medicines and one investigational therapy, will be presented underscoring the company's focus on pursuing targeted therapies for hard-to-treat cancers where few therapies e
Business WirePfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting
NEW YORK, May 25, 2023--Pfizer Inc. (NYSE: PFE) will present data across its Oncology portfolio and growing pipeline, covering multiple tumor types and novel mechanisms of action at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from June 2 through June 6. Abstracts include new data from pivotal trials supporting ongoing regulatory reviews for three potential therapies, if approved, and new clinical data for six early pipeline assets. In addition, Pfizer will hig
Yahoo Finance VideoPfizer trades at pre-pandemic levels, frustrating investors
Yahoo Finance health care reporter Anjalee Khemlani analyzes shares of pharmaceutical giant Pfizer as the FDA issues its full approval of the COVID-19 treatment drug Paxlovid.
BenzingaFDA Nods to Pfizer's Paxlovid for COVID-19: A Potential $8 Billion Lifesaver in 2023
The FDA has approved Pfizer Inc's (NYSE: PFE) Paxlovid (nirmatrelvir and ritonavir) for mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death. The FDA approval is based on safety and efficacy data from the EPIC clinical development program. The Phase 2/3 EPIC-HR study enrolled unvaccinated, non-hospitalized adults aged 18 years and older with confirmed COVID-19 at increased risk of progressing to severe disease. The data s
Motley FoolWall Street Expects These Stocks to Soar 175% and 545%. Should You Buy?
Wall Street has high hopes for certain stocks over the coming 12 months. Two of them are biotech companies that took center stage during earlier days of the pandemic. Both companies raced to bring a coronavirus vaccine to market.
AP FinanceCOVID pill Paxlovid gets full FDA approval after more than a year of emergency use
Pfizer received full approval on Thursday for its COVID-19 pill Paxlovid that's been the go-to treatment against the coronavirus. More than 11 million prescriptions for Paxlovid have been dispensed since the Food and Drug Administration allowed emergency use in late 2021. The emergency status was based on early studies and was intended to be temporary pending follow-up research.
